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Abstract
Recent studies have demonstrated that the chemokine receptor CXCR4 plays a crucial role in organ-specific metas-
tasis formation. Although a variety of studies showed the expression of chemokine receptors, in particular, CXCR4, by
gastrointestinal tumors, the precise mechanisms of chemokine receptor–mediated homing of cancer cells to specific
sites of metastasis remained elusive. Here, we used liver metastatic human HEP-G2 hepatoma and HT-29LMM colon
cancer cells expressing functional CXCR4 to dissect the metastatic cascade by intravital fluorescence microscopy.
Immunohistochemistry revealed that the CXCR4 ligand CXCL12 is expressed by endothelial cells and likely Kupffer
cells lining the liver sinusoids. Tumor cell adhesion and extravasation in vivo was quantitatively analyzed using intra-
vital fluorescence microscopy. Treatment of cells with an anti-CXCR4 antibody did not affect cell adhesion but signifi-
cantly impaired tumor cell extravasation (HEP-G2; isotype control: 22.3% ± 4.3% vs anti-CXCR4: 6.0% ± 5.0%, P <
.001). In addition, pretreatment of tumor cells with the ligand CXCL12 enhanced the activation of the small GTPases
Rho, Rac, and cdc42 as well as tumor cell extravasation without affecting tumor cell adhesion within liver sinusoids.
Taken together, the findings of the present study provide first in vivo insights into the early events of chemokine
ligand/receptor–mediated liver metastasis formation of tumor cells and define tumor cell extravasation rather than
tumor cell arrest as the rate-limiting event.
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Introduction
The occurrence of metastases within distant organs represents the life-
threatening event that limits the survival of patients with malignant
diseases. To form clinically evident metastases, tumor cells have to com-
plete a series of highly regulated steps. This metastatic cascade is initi-
ated by local invasion and intravasation of tumor cells at the primary
site, their subsequent adhesion/arrest is within vessels of target organs,
and is followed by cell migration, leading to the extravasation of tumor
cells [1]. Within target organs, the survival, promotion of tumor cell
growth, and the induction of neoangiogenesis complete the series
of steps finally resulting in successful formation of metastatic foci [2].
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Notably, the early steps of metastasis seem to mimic, in part, events
underlying leukocyte trafficking. Recent findings demonstrate that che-
mokine ligand/receptor interactions critically regulate the firm adhesion
of distinct leukocyte subsets to the endothelium and mediate their
transendothelial migration [3,4]. Subsequently, tumor cells of various
origin have been shown to express distinct patterns of chemokine recep-
torsmediating tumor cell migration, invasion, proliferation, and survival
in vitro [5–8]. In vivo, the overexpression of distinct chemokine recep-
tors on tumor cells, in particular, CXCR4, was enhanced, whereas their
neutralization significantly impaired the formation ofmetastases [9–12].
In clinical studies, the overexpression of the chemokine receptor CXCR4
was associated with an impaired prognosis of patients undergoing sur-
gery for colorectal liver metastasis [13]. In patients with hepatocellular
carcinoma, higher levels of CXCR4 expression were associated with
advanced local tumor progression, metastatic dissemination, and poor
outcome [14]. Although their role in organ-specific metastasis forma-
tion is established, the underlying mechanisms of chemokine receptor–
mediated dissemination of tumor cells remain elusive.
In the present study, we sought to dissect the steps of chemokine
receptor–mediated events during early phases of metastasis in vivo.
Therefore, the interaction of tumor cells with the microvessel system
of the liver, as one major metastatic target organ, was analyzed using
intravital fluorescence microscopy [15,16].
Materials and Methods
Cell Lines and Tissue Specimens
Human Caco-2 (ATCC, Wesel, Germany), HT-29LMM, and
HT-29P (I. Fidler, Houston, TX) colorectal carcinoma cells and human
HEP-G2 hepatocellular carcinoma cells (ATCC) were cultured in
RPMI 1640 medium (GIBCO-BRL, Karlsruhe, Germany) containing
10% fetal bovine serum (GIBCO) or minimum essential medium
alpha medium (GIBCO) containing 20% fetal bovine serum, respec-
tively. Semiconfluent cells were cultured and prepared as previously de-
scribed [17]. After trypsination, cell surface proteins were reconstituted
in serum-free medium containing 1% bovine serum albumin (BSA;
Sigma, Deisenhofen, Germany) before using in all experiments.
Human tissue specimens were taken from surgical specimens after
obtaining informed consent from patients and were routinely fixed in
3.7% formalin and paraffin-embedded.
Immunohistochemistry
Paraffin sections from human colorectal carcinomas and liver metas-
tases from colorectal carcinomas were immunohistochemically stained
for CXCR4 expression as previously described [9].
For the detection of CXCL12 expression, sections of paraffin-
embedded normal human liver samples (n = 10) were fixed and de-
paraffinized. Antigens were unmasked using the DakoCytomation
Target Retrieval (Dako, Hamburg, Germany) and a high-pressure
cooker followed by H2O2 treatment and an avidin and biotin blocking
step (Blocking Kit; Vector, Burlingame, CA). Sections were stained
with monoclonal antibodies directed against human CXCL12 (mouse
immunoglobulin G1 [IgG1], 79018.111; R&D Systems, Minneapolis,
MN) or isotype control antibodies (R&D Systems). Development of
the staining was performed with the Vectastain ABC and AEC kits
(Vector). Sections were counterstained with hematoxylin.
Quantitative Real-time Reverse Transcription–Polymerase
Chain Reaction (TaqMan)
Total RNA of tumor cells was extracted (TRIzol reagent, Invitrogen,
Carlsbad, CA), DNase-treated, and reverse-transcribed as described
previously [9,18]. Complementary DNA (cDNA) was quantitatively
analyzed for the expression of human chemokines and chemokine re-
ceptors by the fluorogenic 5′-nuclease polymerase chain reaction (PCR)
assay as reported [9,18]. Specific primers and probes were obtained
fromApplied Biosystems (FosterCity, CA).Gene-specific PCRproducts
were continuously measured during 40 cycles with the ABI PRISM
7000 Sequence Detection System (Applied Biosystems). Quantitative
real-time reverse transcription–PCR (RT-PCR) was performed with
SYBR green as reporter for reactions using chemokine receptor–specific
primers and 6-carboxylfluorescein as reporter for reactions using chemo-
kine receptor–specific primer/probe combinations. Probes for the inter-
nal positive control (ribosomal 18S RNA) were associated with the VIC
reporter. Target gene expression was normalized between different sam-
ples based on the values of ribosomal 18S RNA expression. Plasmid
cDNA for chemokine receptors were used for quantification of target
gene-specific messenger RNA (mRNA) expression.
Flow Cytometric Analysis of Chemokine Receptors
and Integrin Expression
Flow cytometric analysis of chemokine receptor expression was
performed as previously described [9]. Alternatively, cells were perme-
abilized for intracellular staining by incubating with methanol. For flow
cytometric analysis of integrin expression, cells were trypsinized and
washed in serum-free medium. After reconstitution for 60 minutes,
cells were fixed with fresh 1% paraformaldehyde. Cells were then pro-
cessed as described for CXCR4 detection. The following antibodies
were used: anti–human integrin β1 monoclonal antibody (mAb, clone
P4C10; Chemicon, Hofheim, Germany), anti–human integrin β4 mAb
(clone ASC-8; Chemicon), anti–human integrin β3 (clone N-20; Santa
Cruz, Heidelberg, Germany), anti–human αv mAb (clone 272-17E6;
Calbiochem, Darmstadt, Germany), anti–human α1 integrin mAb
(clone SP2/0; Upstate, Lake Placid, NY), anti–human α2 integrin
mAb (clone 16B4; Serotec, Oxford, United Kingdom), anti–human
α3 integrin mAb (clone ASC-1; Chemicon), anti–human α4 integrin
mAb (kindly provided by J. Eble, Muenster), anti–human α5 mAb
(clone JBS5; Serotec), anti–humanα6mAb (clone 4F10; Serotec).Nega-
tive and isotype controls were processed similarly. Corresponding Alexa
Fluor568–labeled secondary antibodies (Molecular Probes, Leiden, the
Netherlands) were used. Flow cytometry was done using EPIC XL
(Beckman Coulter, Krefeld, Germany).
Static Adhesion Assays
Assays were performed in 96-well microtiter plates coated with
collagen type I (C I; BD Biosciences, San Jose, CA) or fibronectin
(FN; Sigma; each 10μg/ml) as previously described [17]. Serum-starved
reconstituted tumor cells (105) were fluorescence-labeled (CalceinAM;
Molecular Probes) and added to each well in medium containing 1%
BSA. This procedure was reported not to interfere with the adhesive
properties of cells [17]. After the indicated adhesion time, wells were
washed with phosphate-buffered saline (PBS) to remove nonadherent
cells. Fluorescence is expressed as percent fluorescence of unwashed
control wells. The numbers given are representative of independent
triplicate experiments. t Test was used to compare groups. For adhesion
assays on endothelial cells, human umbilical vein endothelial cells
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(HUVECs; kindly provided by B. Löffler, Muenster) were seeded and
grown confluent in 96-well dishes. Before the adhesion assay, HUVECs
were activated by incubation with tumor necrosis factor α (TNF-α)
(10 ng/ml; Sigma) for 12 hours. Reconstituted, fluorescence-labeled
cells (105) were added to each well and processed as described previously.
Tumor Cell Chemotaxis
Chemotaxis was assayed in 24-well cell culture chambers (Greiner
BioOne, Frickenhausen, Germany) using inserts with 8-μmporemem-
branes (Nunc/Thermo Fisher Scientific, Rockford, IL) coated with FN
(10 μg/ml) or C I (10 mg/ml) as described [9]. Cells (2.5 × 105) were
resuspended in serum-free medium containing 1% BSA and were
added to the upper chamber. Serum-free medium containing CXCL12
in indicated concentrations was added to the lower chamber. After
incubation for 18 hours, cells on the upper surface were removed by
cotton swaps and cells on the lower surface of the membrane were fixed
with ice-cold methanol and stained with hematoxylin/eosin. The mem-
branes were removed from the inserts and mounted on microscopic
slides. Cell numbers were counted using a light microscope in 16 stan-
dardized fields at an original magnification of ×16. The numbers given
are means ± SD and compared by a t test. The numbers given are rep-
resentative of three independent experiments.
Intravital Microscopy
The intravital fluorescence microscopy for evaluation of in vivo
tumor cell adhesion and migration into the hepatic parenchyma was
performed as described previously [15]. Briefly, male Sprague-Dawley
rats (250-300 g; Charles River, Deisenhofen, Germany) were cared for
in accordance with the standards of the German Council for Animal
Care under an approved protocol of the local Animal Welfare Commit-
tee. Anesthetized animals obtained a catheter placed into the right
carotid artery with the tip located central to the heart. After a wide me-
dian laparotomy, the left part of the liver was mobilized. Fluorescence
microscopy was performed using an upright epifluorescencemicroscope
(Zeiss, Jena, Germany) containing a 20-fold objective and a timer-
containing S-VHS video system for further analysis (Figure 4A). For
intravital observation of tumor cell interactions with the hepatic sub-
capsular microcirculation, 1 × 106 cells resuspended in 1 ml of calcium
and magnesium–free PBS were injected intra-arterially as a single-cell
suspension for 60 seconds. As described previously [15], this procedure
did not interfere significantly with the cardiocirculatory functions of
the animals. For semiquantitative analysis of cell interactions within
the hepaticmicrocirculation, 28microscopic fields were monitored every
5 minutes for a total of 30 minutes using a standardized procedure. The
total numbers of arrested cells (adherent andmigrated/extravasated) were
counted, and relative migration rates were calculated as the number of
migrated cells/number of arrested cells. The numbers given are means
of n independent experiments (animals injected) for each group and
groups were compared by a t test. Cells were harvested and prepared
as described previously [17]. In some experiments, before injection,
cells were incubated with a neutralizing anti-CXCR4 (MAB 173;
R&D Systems), with an isotype control antibody (R&D Systems), or
with CXCL12 (R&D systems) as indicated.
GTPase Activation Assay
Cells were trypsinized and reconstituted in serum-free medium
containing 1% BSA for 45 minutes. After reconstitution, nonadherent
cells (107) were treated with increasing concentrations of CXCL12
(25-500 ng/ml) or vehicle control for 15 minutes. Cells were then
washed once with ice-cold PBS and lysed with 50 mM Tris-HCl buffer
pH 7.4, containing 150 mM NaCl, 1% NP-40, 0.5% deoxycholate,
0.1% SDS, 5 mM EDTA, and 1 μl of inhibitor cocktail (Sigma) per
1 ml of lysis buffer. Lysates were clarified by centrifugation at 14,000g
for 5 minutes and stored at −80°C before further processing. After pro-
tein quantitation, 30.8 μl of Rho Assay Reagent (Rhotekin RBD glu-
tathione agarose beads; Upstate/Millipore, Eching, Germany) or 10 μl
Rac/cdc42 assay reagent (PAK-1 PBD agarose conjugate; Upstate/
Millipore) were added to 1000 μg of total protein and incubated for
45 minutes at 4°C. Samples were washed three times with magnesium-
containing lysis buffer containing 25 mM HEPES pH 7.5, 150 mM
NaCl, 1% Igepal CA-630 (Sigma), 10% glycerol, 10 mM MgCl2,
1 mM EDTA, and 1 μl of inhibitor cocktail per 1 ml of lysis buffer
(Upstate). The agarose beads were resuspended in 4× Laemmli sample
buffer and boiled for 5minutes. Total protein lysates were used as loading
controls. The lysates were loaded on 12% polyacrylamide gels, then
transferred to polyvinylidene fluoride membranes. and GTPases were
finally detected with rabbit anti–RhoA antibody (Santa Cruz), mouse
anti–Rac antibody (BD Biosciences Pharmingen), and rabbit anti–
Cdc42 antibody (Cell Signaling, Danvers, MA). Bands were visualized
with enhanced chemiluminescence (Millipore).
Atomic Force Microscopy
Tumor cells were analyzed as previously reported [19,20]. Briefly,
cells were placed on a conventional glass slide and fixed with glutar-
aldehyde 2% in a HEPES-buffered solution. Atomic force microscopy
( JPK, Nanowizard) analysis was performed by contact mode and tap-
ping mode in fluid. The scan rate of surface imaging was less than 1 Hz,
and the applied force in case of the contact mode was 0.5 nN. The
spring constant of the cantilever was approximately 0.01 N·m. Images
were analyzed by the software coming with the instrument. For statis-
tical analyses, parameters at indicated time points were compared using
a χ 2 test.
Results
Expression and Anatomical Localization of
CXCR4 and Its Ligand CXCL12
Analysis of the chemokine receptor repertoire of tumor cells of
human colon cancer cells with different liver metastatic potential
revealed that tumor cells with low metastatic potential (Caco-2 and
HT-29P) showed low levels of CXCR4 mRNA expression (Fig-
ure 1A) as well as weak cell surface expression of CXCR4 protein
in 3.5% to 6.8% of tumor cells, respectively (Figure 1A). However,
the liver metastatic subclone HT-29LMM displayed CXCR4 surface
expression in 9.3% to 17.8% of the cells (Figure 1A). Furthermore,
intracytoplasmic staining of fixed tumor cells revealed that 95% of
HT-29LMM cells abundantly store CXCR4 in intracellular pools
(data not shown). The most prominent cell surface expression of
CXCR4 (>90%) was observed in the liver metastatic human hepa-
toma cell line HEP-G2 (Figure 1A). Flow cytometric data paralleled
results obtained by quantitative real-time RT-PCR showing the most
abundant CXCR4 mRNA expression in HT-29LMM and HEP-G2
cells (Figure 1A).
To validate the role of CXCR4 in the process of liver metastasis in
patients with colorectal carcinoma, paraffin sections of primary tumors
(n = 7) and liver metastases (n = 38) of colorectal carcinoma patients
were analyzed for CXCR4 expression using immunohistochemistry.
Six of 7 primary tumors and 27 of 38 liver metastases showed a marked
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expression of CXCR4 by tumor cells (Figure 1, B and C). Moreover,
dissociated single tumor cells also maintained a strong membrane as
well as cytoplasmic expression of CXCR4 (data not shown).
Although we previously demonstrated that the CXCR4 ligand
CXCL12 is highly expressed in human liver using quantitative real-time
RT-PCR [9], it remained unclear which liver-residing cells express
CXCL12 protein and where this chemokine is presented to metastatic
tumor cells within the sinusoidal vessel system of the liver. Immunohisto-
chemical analyses of normal human liver revealed that CXCL12 is ex-
pressed at the interface between the sinusoidal vessel system and the
liver parenchyma (Figure 1, D and E ). Sinusoidal endothelial cells
lining the sinusoidal wall as well as other disseminated cells, likely repre-
senting Kupffer cells, stained positive for CXCL12 (Figure 1E). Thus,
this chemokine is perfectly positioned to interact with circulating tumor
cells during early steps of metastasis formation.
Having established that liver metastatic tumor cells express CXCR4
and that the corresponding ligand CXCL12 is readily accessible at the
interface of the sinusoidal lumen and the extravascular parenchyma,
we sought to investigate whether chemokine/chemokine receptor
interactions play a role in tumor cell adhesion to the sinusoidal vessel
wall and/or in tumor cell extravasation from the liver sinus into the
liver parenchyma.
Epithelial Tumor Cell Adhesion to Extracellular Matrix
and Endothelial Cells Is Independent of
CXCL12/CXCR4 Interactions
Previously, we demonstrated that direct interaction of circulating
tumor cells with hepatic extracellular matrix (ECM) components,
such as C I and FN, within the Disse space can mediate metastatic
tumor cell arrest of tumor cells within the liver [21,22]. To assess the
Figure 1. Metastatic human colon carcinoma cells express CXCR4 and its corresponding chemokine ligand CXCL12 is located at the
interface between the sinusoidal vessel system and the liver parenchyma. (A) Cell surface as well as mRNA expression of CXCR4 by
different human colon carcinoma cells (Caco-2, HT-29P, HT-29LMM) and the liver metastatic hepatocellular carcinoma cell line HEP-G2
correlates with their in vivo metastatic potential. Representative results of triplicate experiments. Target gene expression is presented
as femtograms per 25 ng of cDNA. (B and C) Immunohistochemical evaluation of CXCR4 in a representative primary tumor (B) and liver
metastasis (C) of colorectal cancer. Strong expression of CXCR4 (arrowhead) by colon cancer cells. Positive staining is indicated as red
(9-amino-ethylcarbazole). Original magnification, ×100. (D and E) Immunohistochemical analysis of CXCL12 expression in normal human
liver. (D) CXCL12 protein expression in the subcapsular region and sinusoidal microvessel system. Original magnification, ×40. (E) Strong
CXCL12 expression is lining the inner surface of the liver sinusoids (black arrowheads) and present in disseminated cells, likely representing
Kupffer cells (white arrowhead). Original magnification, ×200.
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Figure 2. CXCL12 does not enhance metastatic tumor cell adhesion to ECM components present in the Disse space or to activated endo-
thelial cells. (A and B) HEP-G2 (A) and HT-29LMM (B) cells showed time-dependent adhesion to FN and C I representing the main compo-
nents of the hepatic ECM, which is readily accessible in the Disse space as well as to activated (TNF-α; 10 ng/ml for 12 hours) HUVECs.
Short-term stimulation of the cells with CXCL12 (500 ng/ml for 15 minutes) did not enhance cell adhesion to these ECM components or to
endothelial cells at any time interval (t test, P > .05). (D) Expression of integrin subunits by HEP-G2 cells determined by flow cytometry.
Epithelial HEP-G2 tumor cells do not express the integrin α4 subunit. Representative results of triplicate experiments are shown.
Neoplasia Vol. 11, No. 7, 2009 CXCR4 Regulates Tumor Cell Extravasation In Vivo Gassmann et al. 655
adhesive properties of HEP-G2 and HT-29LMM to these matrix
proteins as the main components of the ECM of the liver [22,23], we
used in vitro adhesion assays. HEP-G2 (Figure 2A) and HT-29LMM
cells (Figure 2B) showed cell adhesion to immobilized FN or C I in a
time-dependent manner (5-30 minutes). Stimulation of these cells with
CXCL12 (500 ng/ml) for 15 minutes before placement on the ECM
components did not change their adhesive properties in vitro (Figure 2,
A and B). Because circulating tumor cells may also adhere to endothelial
cells within the capillary system of target organs, we performed adhe-
sion assays on TNF-α–stimulated HUVECs. CXCL12 treatment of
Figure 3. CXCL12/CXCR4 interaction results in the activation of small GTPases and in the induction of a migratory phenotype. (A) Chemo-
tactic response of HEP-G2 cells to different concentrations of CXCL12 in a transwell migration assay. The migratory response is attenuated
in cells treated with a neutralizing anti-CXCR4 antibody (t test, *P < .05, **P < .001). Representative results of triplicate experiments are
shown. (B and C) InWestern blot–based GTPase activation assays after short-term stimulation (15 minutes) of HEP-G2 and HT-29LMM cells
with increasing concentrations of CXCL12, HEP-G2 cells showed an increased Rac activation level, whereas the Rho activity level remained
unchanged. In contrast, HT-29LMM cells showed increased Rho activation, whereas Rac activity was unaffected after CXCL12 stimulation.
(C) The presence of CXCL12 also induced a concentration-dependent cdc42 activation in HEP-G2 cells. In HT-29LMM cells, cdc42 activity
was modulated by CXCL12 in a variable manner. Representative results of triplicate experiments are shown. (D and E) Atomic force micros-
copy demonstrated that tumor cells elongate and flatten their lamellipodia upon stimulation with CXCL12. The lines in the images represent
the areas of measurements. (F) Determination of CXCL12-induced changes in the width of the lamellipodium of stimulated tumor cells. The
width decreases from 12 to 6 μmafter 10minutes of CXCL12 stimulationwith a partial recovery to a width of 10 μmafter 30minutes (χ2 test,
P < .05; measured 5 μm proximal from the leading edge; n > 10). (G) The slope of single tumor cells measured by the angle between the
beginning of the lamellipodium and 3 μm proximal. Upon CXCL12 stimulation, tumor cells flattened by 12 degrees and again showed a
partial recovery after 30 minutes (χ2 test, P < .05; n > 10 for each experiment).
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HEP-G2 or HT-29LMM cells also did not promote their adhesion to
stimulated HUVEC (P > .05). Only stimulated HT-29LMM showed
a tendency to enhanced adhesion to HUVEC and FN after 30 minutes
(P > .05; Figure 2, A or B).
Because increased adhesion of different tumor entities to endothelial
cells through α4β1- and α5β1-integrins has been reported [12,24,25],
we analyzed the integrin repertoire of the epithelial cancer cells used
in this study. Generally, the expressed integrin repertoire enables these
cells to adhere to the directly accessible ECM in the Disse space within
the hepatic sinusoids [21,22]. However, integrin expression of HT-
29LMM (data not shown) or HEP-G2 cells (Figure 2D) revealed that
these liver metastatic epithelial tumor cells show only weak expression
of the integrin α5 subunit and do not express the integrin α4 subunit
that would eventually mediate adhesion to endothelial structures in a
CXCL12-dependent fashion. However, HT-29LMM (data not shown)
or HEP-G2 cells (Figure 2D) demonstrated the abundant expression of
αv-, α2-, and α6-integrins mediating the adhesion to FN and C I in the
Disse space [21,26].
Chemokine CXCL12 Induces Tumor Cell Migration
To define the functional activity of CXCR4 expressed by tumor cells,
Transwell migration assays were used. The CXCR4 ligand CXCL12
induced concentration-dependent chemotactic responses of HEP-G2
cells (Figure 3A). Chemotactic responses were significantly impaired
in the presence of a neutralizing anti-hCXCR4 antibody indicating
that CXCR4 is functionally active on HEP-G2 cells and required for
CXCL12-induced directional migration (Figure 3A). Because chemo-
kine receptors are known to promote chemotactic cell motility and
cytoskeletal rearrangement through small GTPases, we analyzed the
activation level of Rho, Rac, and cdc42 in HEP-G2 and HT-29LMM
tumor cells. Both cell lines showed a specific pattern of GTPase activa-
tion in response to CXCL12 stimulation (Figure 3, B and C ). Upon
stimulation of HEP-G2 cells with different concentrations of CXCL12
(0, 25, 500 ng/ml), the Rho activation level was not significantly al-
tered compared with unstimulated cells (Figure 3B). In contrast, the
Rac activation level was increased after a low-dose stimulation with
25 ng/ml CXCL12 (Figure 3B). In addition, the presence of CXCL12
increased the cdc42 activation level in a concentration-dependent
manner in HEP-G2 cells (Figure 3C ).
In HT-29LMM cells, we found a slightly different pattern of
GTPase activation with increasing activity of Rho upon CXCL12
stimulation up to the maximum dose of 500 ng/ml (Figure 3B). In con-
trast, no significant activation of Rac was observed at high doses
(Figure 3B). Cdc42 activity was modulated by CXCL12 in a variable
manner without stringent concentration dependency in HT-29LMM
cells (Figure 3C).
To visualize and quantify cell morphology alterations upon chemo-
kine stimulation, we used atomic force microscopy. Atomic force mi-
croscopy has evolved to the imaging method that yields the greatest
structural details on live, biological samples. It can be used to study
the three-dimensional surface topography of single cells in a physiologi-
cal buffer solution. The detection limits are 10 nm for the height (z-axis)
and approximately 100 nm for the lateral axes (x- and y-axes). In the
present study, HEP-G2 tumor cells were analyzed after different periods
of CXCL12 stimulation. Alterations of lamellipodia were documented
by measuring the cell width and the slope of single lamellipodium. We
could show that upon chemokine stimulation, single tumor cells show a
flattening of their lamellipodia represented by a decrease of the cell
width and a drop of the angle between the leading edge and cell body
(Figure 3,D and E). These morphologic alterations could be measured
already after 10 minutes of chemokine stimulation. Interestingly, after
20 and 30 minutes of stimulation, respectively, a slight recovery of the
measured morphologic alterations was documented indicating a follow-
upmovement of the cell body (Figure 3, F andG). These data represent
morphologic changes of the cells corresponding to Rac activation and
Figure 3. (continued).
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indicate that chemokine stimulation activates tumor cells within min-
utes to form a lamellipodium as a prerequisite to start cell migration.
CXCR4 Induces the Early Extravasation of Metastatic Tumor
Cells into the Liver Parenchyma In Vivo
To evaluate the role of CXCL12/CXCR4 interactions for tumor cell
adhesion and migration/extravasation in vivo, we used our previously
described intravital fluorescence microscopy model [15,16,21] to study
these initial steps during the formation of liver metastases (Figure 4A).
Thismodel allows the direct observation ofmetastatic tumor cells within
the superficial sinusoidal microvessel system of the liver. The number
of arrested cells within the liver sinusoids (Figure 4B) and the relative
numbers of extravasated/migrated cells (Figure 4C ) were quantified
in vivo. Previously, we confirmed the early extravasation of tumor cells
using three-dimensional laser scanning microscopy [16].
Because liver metastatic HEP-G2 and HT-29LMM cells showed
the highest expression of CXCR4 in vitro, these tumor cell lines were
chosen for further intravital fluorescence microscopy experiments.
Tables of the supplemental material give detailed numbers and statistics
of in vivo cell adhesion and extravasation for HEP-G2 (Table W1) and
HT-29LMM cells (Table W2).
The total number of arrested untreated HEP-G2 (n = 13 indepen-
dent experiments), isotype control-treated HEP-G2 (n = 8 independent
experiments), and isotype control-treated HT-29LMM (n = 8 indepen-
dent experiments) cells reached 55.4 ± 14.6, 44.2 ± 3.2, and 59.0 ±
11.8 cells/28 microscopic fields, respectively, within 30 minutes after
tumor cell injection (Figure 4, F, D, and H ). The rates of early tumor
cell extravasation/migration of untreated HEP-G2 (n = 13 independent
experiments), isotype control-treated HEP-G2 (n = 8 independent ex-
periments), and isotype control treated HT-29LMM (n = 8 indepen-
dent experiments) cells reached 18% ± 11%, 22% ± 4%, and 9% ±
3%, respectively, of all arrested cells within 30 minutes after tumor cell
injection (Figure 4, G , E , and I ). To determine the functional role of
CXCR4 for adhesion and extravasation/migration of metastatic tumor
cells in vivo, HEP-G2 cells were treated with a neutralizing anti–human
CXCR4 antibody before injecting into Sprague-Dawley rats (n = 12
independent experiments). Most interestingly, blocking of CXCR4
signaling did not affect the adherence of tumor cells within the hepatic
microcirculation (isotype control: 44.2 ± 3.4 cells/28 microscopic vs
anti-CXCR4: 49.4 ± 24.8 cells/28 microscopic; P = .184; Figure 4D);
however, the rates of migrated/extravasated cells were significantly de-
creased from a maximum of 22% ± 4% in the isotype-treated group to
6% ± 5% after anti-hCXCR4 treatment (P < .001; Figure 4E). Using
liver metastatic human HT-29LMM colon cancer cells, blocking of
CXCR4 (n = 8 independent experiments) resulted in a slightly reduced
adhesion that did not reach a significant level at all time intervals (Fig-
ure 4H ), but extravasation of HT-29LMM was significantly impaired
after inhibition of CXCR4 (Figure 4I).
To investigate whether CXCL12 can induce a “specific” extravasation
program in tumor cells, we stimulated tumor cells with CXCL12 pro-
tein (500 ng/ml) for 15 minutes before in vivo injection. In fact,
CXCL12 treatment did not affect the adherence of HEP-G2 (n = 7
independent experiments; Figure 4F ) or HT-29LMM cells (n = 9
independent experiments; Figure 4I) to the vessel wall of the liver sinu-
soids in vivo but significantly enhanced the rates of extravasated cells to
amaximumof 41%± 3%compared with 18%± 11%of vehicle-treated
HEP-G2 cells (P < .001; Figure 4G). Comparing the migration rates of
isotype control-treated and CXCL12-treated cells, similar results were
observed for HT-29LMM between 15 and 30 minutes after cell injec-
tion (Figure 4I ). At the end of the observation period, the rate of ex-
travasated isotype control-treated HT-29LMM cells was significantly
lower with 9% ± 3% compared with 20% ± 8% of CXCL12-treated
cells (P = .003).
Taken together, intravital fluorescence videomicroscopy analyses iden-
tified for the first time CXCR4-independent adhesion, but CXCL12/
CXCR4 triggered extravasation of metastasizing tumor cells in the early
phase of liver colonization.
Discussion
Colorectal cancer shows a high prevalence of liver metastasis and the
clinical course of hepatocellular carcinoma is frequently dominated
by intrahepatic metastasis [27]. For example, after liver transplantation,
recurrence of hepatocellular carcinoma within the transplanted liver
likely reflects an organ-specific homing of circulating tumor cells into
the allograft [28]. Previous studies demonstrated a role for the chemo-
kine receptor CXCR4 in the dissemination of colorectal cancer to the
liver [13], in local and systemic progression of hepatocellular carcinoma
[14], as well as in metastasis formation of other tumor entities [29,30].
However, the precise mechanisms of chemokine-mediated liver metas-
tasis formation remained elusive.
Migratory and adhesive properties of tumor cells are critical param-
eters for the development of metastasis [31]. We previously demon-
strated that CXCR4 can mediate directional migration and metastasis
of human breast cancer cells [9]. Although the CXCR4 ligand CXCL12
is highly expressed within human liver using quantitative real-time
RT-PCR [9], it remained unclear which liver-residing cells express
CXCL12 protein and where this chemokine is presented to metastatic
tumor cells within the sinusoidal vessel system of the liver. Immunohisto-
chemical analyses of normal human liver specimens revealed that
CXCL12 is expressed at the interface between the sinusoidal vessel sys-
tem and the liver parenchyma. Sinusoidal endothelial cells lining the
microvascular hepatic vessel wall, as well as disseminated cells, likely
representing Kupffer cells, abundantly presented CXCL12 protein.
Thus, this chemokine is perfectly positioned to interact with circulating
tumor cells during early steps of metastasis formation.
To investigate the mechanisms of chemokine receptor–mediated
events during early phases of metastasis in vivo, we monitored the inter-
actions of tumor cells with the microvessel system of the liver sinusoids
by intravital fluorescence microscopy [15]. Taking advantage of this
model, we previously reported that tumor cells with different liver
metastatic potential showed no significant differences in adhesion to
liver sinusoids [16]. In contrast to their adhesive properties, the ability
of tumor cells to extravasate into the liver parenchyma correlated
with their metastatic potential [16]. In the present study, inhibition
of CXCR4 signaling of colorectal cancer and hepatocellular carci-
noma cells showed unaffected adhesion within the hepatic micro-
vasculature in vivo, but tumor cell extravasation was significantly
impaired after blockade of CXCR4 signaling. In corresponding
in vivo experiments, stimulation of tumor cells with CXCL12 accelerated
migration/extravasation but did not affect adhesion to endothelial cells
or ECM components.
Taken together, intravital fluorescence videomicroscopy analyses
identified for the first time that liver metastatic epithelial tumor cells
exhibit CXCR4-independent adhesive properties in vivo but demon-
strate CXCR4-regulated extravasation into the liver parenchyma upon
interaction with its specific ligand CXCL12.
These results were surprising because enhanced tumor cell adhesion
to endothelial cells because of CXCL12 treatment was reported for other
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Figure 4. CXCL12/CXCR4 interactions promote early extravasation of metastatic tumor cells in vivo. (A–C) Intravital microscopy setup. A
median laparotomy was performed in anesthetized rats. The left part of the liver lobe (arrows) is carefully mobilized and positioned under
an upright fluorescence microscope for an observation period of 30 minutes. (B and C) After injection of 106 fluorescence-labeled tumor
cells into the left ventricle, cells enter the sinusoidal vessel system, become adherent to the sinusoidal wall (B; sinusoidal wall outlined),
and extravasate (C; sinusoidal wall outlined). Scale bars, 50 μm. Adhesion and migration are quantified using a standardized procedure.
(D and E) CXCR4 neutralization did not impair tumor cell adhesion to the sinusoidal wall (D) but significantly impaired extravasation of
HEP-G2 cells into the liver parenchyma in vivo (E). (F and G) Treatment of tumor cells with the CXCR4 ligand CXCL12 before injection did
not affect cell adhesion within the liver sinusoids (F) but facilitated tumor extravasation (G). (H and I) Using HT-29LMM cells too, CXCR4
neutralization or CXCR4 stimulation did not affect tumor cells adhesion to the sinusoidal wall (H). In contrast, CXCR4 neutralization
impaired, and CXCR4 stimulation by its ligand CXCL12 facilitated tumor cell extravasation (I). *P < .05; **P < .001.
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tumor entities, such as small cell lung cancer, myeloma, and melanoma
cells [12,24,25]. Nonepithelial tumor cell adhesion to endothelial
cells and ECM was mainly mediated by α4β1-integrins and partly by
α5β1-integrins, respectively [12]. Upon chemokine stimulation, α4β1-
integrin avidity and affinity were increased [12,24], and Arg-Gly-Asp–
dependent adhesion to FN or laminin was stimulated [32]. In breast
cancer cells, facilitated phosphorylation of focal adhesion kinase and in-
creased adhesion to FN after CXCL12 stimulation were reported [33].
Because HT-29LMM and HEP-G2 cells do not express the integrin α4
subunit and show only weak expression of the integrin α5 subunit, their
adhesion to the endothelium cannot be mediated by α4-integrins but
seems to be mainly mediated by CXCR4-independent systems such
as sialylated glycoproteins or Thomson-Friedenreich glycoantigen as
ligands for endothelial selectins [21,34] and galectin-3 [35], respectively.
In contrast, migration of carcinoma cells along C I bundles reaching
from the subendothelial Disse space into the interstitium between hepa-
tocytes appears to be an important property for metastatic extravasation
into the liver [22]. CXCL12 was shown to accelerate undirected cancer
cell motility [36] as well as inducing directed chemotaxis of epithelial
cancer cells [37].Here, we show for the first time that theCXCR4 ligand
CXCL12 is presented to adhering tumor cells by the endothelium lining
the sinusoidal vessel wall and by Kupffer cells. Furthermore, chemo-
kines, such as CXCL12, can also be presented by ECM proteins [38]
that are directly accessible in the sinusoids for adhering cells [21].
Chemokine receptor– and other G protein–coupled receptor–
meditated induction of cell motility is critically dependent on the acti-
vation of small GTPases such as the Rho family. RhoA and RhoC
promote the formation of actin stress fibers and the generation of
contractile forces, whereas Rac was found to promote the formation
of lamellipodia. Cdc42 is associated with the formation of microspikes
to sense chemotactic gradients. In osteosarcoma cells, chemokine-
induced cell migration involves RhoA signaling, which seems to be
critically involved in experimental metastasis [39]. In contrast, in breast
cancer cells, Rac and cdc42 promote migration and invasion in a Rho-
independent manner [40]. Using sarcoma cells, other reports [41]
indicated that invasive cancer cells can use different modes of cell
migration depending on the type of activated GTPases. Whereas Rho
activation promoted tumor cell invasion as an ameboid migration
phenotype, Rac activation resulted in the invasion as elongated cells.
These results indicate that activation of either Rho or Rac can induce
tumor cell invasion depending on the cell type and the surrounding
conditions that are determined by the microenvironment of metastatic
target organs. In the present study, CXCL12 stimulation resulted in
Rho activation in HT-29LMM colon cancer cells and in Rac activation
and lamellipodia formation in HEP-G2 hepatoma cells. Nevertheless,
both pathways, through Rho or Rac, seem sufficient in mediating
CXCR4 signaling and inducing cell migration as well as extravasation
in vivo. In both cell lines, CXCL12-induced cdc42 activity may have
facilitated the sensing of chemotactic gradients within the hepatic sinu-
soids and thereby act synergistically with Rho or Rac to promote tumor
cell extravasation within the liver.
Taken together, intravital fluorescence microscopy allowed us to
dissect the early steps of liver metastases formation. The chemokine
CXCL12 is ideally positioned at the interface between the sinusoids
and the liver parenchyma to interact with circulating, metastatic, and
CXCR4-expressing tumor cells. Furthermore, sequestering of CXCL12
through binding to FN or glycosaminoglycans [38] that are present in
the Disse space may also support CXCL12/CXCR4–induced tumor
cell extravasation from the liver sinuses into the parenchyma. Neverthe-
less, CXCL12/CXCR4 interactions obviously do not favor adhesion of
epithelial cancer cells to the endothelium or to ECMcomponents within
the liver. CXCL12/CXCR4 interactions promote early extravasation of
liver metastatic epithelial cancer cells and can thereby determine a crit-
ical step in organ-specific metastases formation. Understanding these
mechanisms is of particular importance because a variety of small mol-
ecule antagonists against chemokine receptors, including CXCR4, are
currently under preclinical or clinical evaluation and may be available
for the treatment of cancer patients in the years to come.
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Table W1. In Vivo Adhesion and Extravasation of HEP-G2.
HEP-G2 In Vivo Time Interval After Cell Injection (min)
0-5 6-10 11-15 16-20 21-25 26-30
Untreated, vehicle control (n = 13) Adhesion ± SD (cells/28 microscopic fields) 47.9 ± 15.2 49.4 ± 17.5 56.1 ± 12.8 60.0 ± 19.2 56.4 ± 15.1 55.4 ± 14.6
Extravasation (%) 3.0 ± 3.1 12.5 ± 8.2 14.1 ± 7.3 14.0 ± 8.8 16.2 ± 12.3 18.3 ± 11.5
IgG 2b isotype control (n = 8) Adhesion ± SD (cells/28 microscopic fields) 33.3 ± 8.0 43.0 ± 4.0 44.8 ± 5.7 43.4 ± 5.9 48.7 ± 11.9 44.2 ± 3.4
Extravasation (%) 2.9 ± 3.1 9.1 ± 2.8 12.9 ± 2.9 18.3 ± 4.3 20.6 ± 2.3 22.3 ± 4.3
Anti-CXCR4 (n = 12) Adhesion ± SD (cells/28 microscopic fields) 34.9 ± 13.0 51.2 ± 19.5 48.0 ± 19.3 48.4 ± 21.0 46.2 ± 12.1 49.4 ± 24.8
Extravasation (%) 1.0 ± 2.4 3.3 ± 4.0 6.2 ± 5.4 7.0 ± 6.9 7.4 ± 8.2 6.0 ± 5.0
CXCL12 (n = 9) Adhesion ± SD (cells/28 microscopic fields) 38.0 ± 6.8 54.3 ± 7.7 56.3 ± 12.8 55.9 ± 14.8 58.9 ± 13.7 57.6 ± 6.1
Extravasation (%) 23.5 ± 2.4 32.7 ± 3.5 36.5 ± 2.9 37.1 ± 2.1 38.1 ± 5.1 40.6 ± 3.5
t Test (P)
IgG 2b isotype vs anti-CXCR4 Adhesion .639 .153 .368 .200 .467 .184
Extravasation .092 .002 .005 .001 <.001 <.001
IgG 2b isotype vs CXCL12 Adhesion .121 .489 .972 .632 .717 .717
Extravasation <.001 <.001 <.001 <.001 <.001 <.001
Table displays detailed results and statistics of tumor cell adhesion and extravasation in vivo using HEP-G2. Relative migration/extravasation rates were calculated as percentage of cells localized within
the liver parenchyma in relation to the total number of arrested cells.
Table W2. In Vivo Adhesion and Extravasation of HT-29LMM.
HT-29LMM In Vivo Time Interval After Cell Injection (min)
0-5 6-10 11-15 16-20 21-25 26-30
IgG 2b isotype control (n = 8) Adhesion ± SD (cells/28 microscopic fields) 48.2 ± 13.3 51.0 ± 20.2 57.7 ± 23.9 58.5 ± 16.8 57.5 ± 20.3 59.0 ± 11.8
Extravasation (%) 8.7 ± 4.3 9.4 ± 4.8 9.8 ± 7.1 10.1 ± 4.0 10.0 ± 6.4 8.7 ± 2.5
Anti-CXCR4 (n = 12) Adhesion ± SD (cells/28 microscopic fields) 33.3 ± 13.0 42.3 ± 16.7 43.9 ± 17.3 38.4 ± 16.6 43.7 15.3 42.1 ± 14.3
Extravasation (%) 2.2 ± 3.3 5.0 ± 5.8 6.5 ± 2.6 5.4 ± 2.6 3.0 ± 3.2 4.7 ± 5.8
CXCL12 (n = 9) Adhesion ± SD (cells/28 microscopic fields) 41.4 ± 25.5 53.4 ± 26.9 51.9 ± 25.6 46.5 ± 18.8 50.4 ± 24.8 49.5 ± 25.7
Extravasation (%) 11.2 ± 5.5 14.1 ± 5.2 20.1 ± 9.7 19.1 ± 5.7 20.0 ± 11.3 19.7 ± 8.5
t Test (P)
IgG 2b isotype vs anti-CXCR4 Adhesion .039 .364 .207 .030 .147 .022
Extravasation .005 .116 .234 .013 .015 .092
IgG 2b isotype vs CXCL12 Adhesion .511 .839 .636 .175 .529 .354
extravasation .317 .069 .027 .002 .043 .003
Table displays detailed results and statistics of tumor cell adhesion and extravasation in vivo using HT-29LMM. Relative migration/extravasation rates were calculated as percentage of cells localized within
the liver parenchyma in relation to the total number of arrested cells.
